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As polyomavirus major capsid protein VP1-derived virus-like particles (VLPs) have been demonstrated to be highly immunogenic, we studied
their interaction with human dendritic cells (hDCs). Exposure of hDCs to VLPs originating from murine (MPyV) or hamster polyomavirus
(HaPyV) induced hDC maturation. In contrast, exposure of hDCs to VLPs derived from human polyomaviruses (BK and JC) and simian virus 40
(SV40) only marginally induced DC maturation. The hDCs stimulated by HaPyV- or MPyV-derived VLPs readily produced interleukin-12 and
stimulated CD8-positive T-cell responses in vitro. The highest frequencies of activated T cells were again observed after pulsing with HaPyV- and
MPyV-derived VLPs. Monocyte-derived hDCs both bound and internalized the various tested polyomavirus VP1-derived VLPs with different
levels of efficiency, partially explaining their individual maturation potentials. In conclusion, our data suggest a high variability in uptake of
polyomavirus-derived VLPs and potency to induce hDC maturation.
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properties. However, due to the absence of viral nucleic acid,
they are non-infectious. The structural similarity of VLPs to the
original viruses has been exploited to investigate the fine
structure of viral capsids, their assembly processes and potential
cell receptor–virus interactions. In addition, VLPs have been
utilized for vaccine and gene transfer development as well as for
serodiagnosis of virus infections (for reviews, see Ulrich et al.,
1998, 2002; Pumpens and Grens, 2002; Noad and Roy, 2003;
Tegerstedt et al., 2005).
Different polyomavirus-derived VLPs can be generated in an
array of systems including insect cells and E. coli by
heterologous synthesis of the major capsid protein VP1
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1991; Forstova et al., 1993; Kosukegawa et al., 1996; Pawlita et
al., 1996; Chang et al., 1997; Voronkova et al., in press).
Expression of murine polyomavirus (MPyV) VP1 in E. coli
allowed the generation of capsomer subunits that assemble to
VLPs under specific ion and pH conditions (Salunke et al.,
1986; Schmidt et al., 1999). A previously described yeast
expression system allowed the high-level expression and self-
assembly of VP1 of avian and mammalian, human and non-
human, polyomaviruses, namely the avian Budgerigar fledgling
disease polyomavirus (BFDPyV), hamster polyomavirus
(HaPyV), MPyV, simian virus 40 (SV40), BK polyomavirus
(BKPyV) and JC polyomavirus (JCPyV) (Sasnauskas et al.,
1999, 2002). Although the native polyomavirus capsid contains
the additional minor capsid proteins VP2 and VP3, the above
cited investigations demonstrated that both proteins are
dispensable for VLP assembly.
Polyomaviruses and polyomavirus-derived VLPs have
become important tools to study general immunological
phenomena. Differences in the susceptibility of two mouse
strains to MPyV infection and tumor formation have been
explained by differences in the CD8-positive T-cell response
(Moser and Lukacher, 2001; Welsh et al., 2002). Moreover,
CD94-NKG2A inhibitory receptors were demonstrated to
induce a polyomavirus-reactive CD8-positive T-cell population
to become anergic (Moser et al., 2002). Recently, quantitative
differences in expression of TLR2 and TLR4 among different
antigen-presenting cell (APC) subpopulations have been
detected in susceptible and resistant mouse strains (Velupillai
et al., 2006). Interestingly, MPyV and MPyV-VP1-derived
VLPs elicited in these strains the same host-specific cytokine
responses (Velupillai et al., 2006). Whereas polyomavirus
infection of mice has been shown to result in the induction of an
antiviral T-cell-independent antibody response, recombinant
VP1 and VP1-derived VLPs failed to do so in some systems
(Szomolanyi-Tsuda et al., 1998, 2001) but not in others (Vlastos
et al., 2003). In addition, MPyV-derived VLPs proved to induce
a protective immunity in mice against specific MPyV-induced
tumors (Franzen et al., 2005).
Dendritic cells (DCs) are professional APCs which possess
the capability to efficiently initiate and modulate cell-mediated
immunity. Immature DCs take up and process antigens.
Activation of APCs can be mediated by a wide variety of
stimuli, such as inflammatory cytokines, microbial products
and CD40L. This maturation is associated with upregulation of
costimulatory molecules (i.e. CD80 and CD86) as well as
antigen-presenting molecules (MHC classes I and II). After
DCs are activated, endocytosis is down-regulated, and the
mature DCs migrate toward regional lymph nodes, where they
activate antigen-specific naive T cells. A wide range of
pathogens trigger this kind of primary immune reaction (for
reviews, see Banchereau and Steinman, 1998; Banchereau et
al., 2000; Guermonprez et al., 2002). However, basic knowl-
edge about underlying mechanisms of the immune responses
induced by polyomavirus major capsid protein VP1 during
viral infection or upon immunization is only very limited
(Lenz et al., 2001).In the present paper, we investigate the human DC (hDC)
maturation potential of VP1-derived VLPs of various poly-
omaviruses. To elucidate the observed different maturation
potentials, we measured the uptake level of these VLPs by
hDCs.
Results
The induced level of maturation of human dendritic cells
differed between VP1-derived VLPs of rodent and primate
polyomaviruses
The immunophenotypic maturation of hDCs was examined
after 48 h of stimulation with polyomavirus VP1-derived VLPs.
More than 75% of the harvested cells visually depicted the
typical morphological features of hDCs. FACS analysis showed
that after differentiation to hDCs the prepared cells were CD14-
and CD3-negative (data not shown).
The hDCmaturation induced by polyomavirus-derived VLPs
was evaluated by flow cytometry analysis of cell surface
markers. Pulsing of hDCs with VLPs originating from rodent
polyomaviruses HaPyV and MPyV resulted in markedly
increased levels of maturation markers CD83, CD80, CD86,
MHC class I (HLA ABC) andMHC class II (HLADRDQ) (data
not shown). For all surface molecules, the level of upregulation
was higher for HaPyV-derived VLPs than for MPyV-derived
VLPs. In contrast, incubation of hDCs with SV40- and human
polyomavirus JCPyV- and BKPyV-derived VLPs resulted in
only very slightly increased levels of CD86, whereas the level of
all other surface molecules was not affected (CD83, CD80,
MHC class I and class II). In our negative controls, untreated
hDCs and hDCs treated with “mock VLPs” (for details, see
Materials and methods), no increased expression of maturation
markers could be detected (data not shown).
A functional test of hDC activation is the degree of reduced
uptake of antigens by macropinocytosis and receptor-mediated
endocytosis (Salter and Dong, 2001). The macropinocytotic
capacity was measured by FACS analysis of Lucifer Yellow
uptake, similarly the receptor-mediated endocytosis was studied
by the FITC-conjugated dextran uptake (Fig. 1). Comparison of
the uptake observed for untreated or “mock VLPs”-treated cells
on the one hand and LPS-treated cells on the other demonstrated
the validity of the assay. In general, the detection of the reduced
uptake of FITC–dextran was more sensitive than that of Lucifer
Yellow. VLPs from MPyV and HaPyV demonstrated a slight
reduction of the Lucifer Yellow and a more pronounced
reduction of the FITC–dextran uptake. In contrast, SV40-,
BKPyV- and JCPyV-derived VLPs had no or only a very slight
influence on the internalization of FITC–dextran or Lucifer
Yellow.
Human dendritic cells pulsed with VLPs of rodent
polyomaviruses, but not SV40, BKPyV and JCPyV showed
the induction of a VP1-specific T-cell response in vitro
The secretion of interleukin-12 (IL-12) by hDCs is one of the
crucial steps to induce an effective T-cell response, in particular
Fig. 1. Uptake levels of FITC–dextran and Lucifer Yellow by VLP-pulsed
hDCs as a functional maturation marker. The hDCs were pulsed with
BKPyV-, JCPyV-, SV40-, MPyV- or HaPyV-derived VLPs, “mock” VLPs
and LPS or were left untreated. After 48 h of incubation, the hDCs were
exposed to Lucifer Yellow or FITC–dextran for 4 h at 37 °C. As a control for
unspecific binding or uptake, cells treated in parallel were kept at 4 °C. The
columns represent the mean values of three independent experiments, the
given error bars indicate the standard deviation.
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measured 48 h after pulsing hDCs with VLPs (Fig. 2). The
ELISA detected elevated IL-12 levels in the media of cells
stimulated with LPS and rodent polyomavirus-derived VLPs.
HaPyV-derived VLPs induced a higher level of IL-12 secretion
than MPyV-derived VLPs. Compared to “mock VLPs”-treated
cells, hDCs treated with VLPs originating from primate
polyomaviruses did not show any increased level of IL-12
secretion.
DCs are the main cell type capable of inducing primary T-
cell responses. The induction of T-cell responses was evaluated
using autologous HLA A2-restricted T cells co-cultivated with
hDCs that had been pulsed with VLPs. After two stimulation
cycles of the autologous peripheral blood lymphocytes (PBL)
with pulsed hDCs, the T cells were stimulated with the
corresponding VLPs and stained for interferon (IFN)-gamma
secreting CD8-positive T cells (Fig. 3). In the negative controlsFig. 2. IL-12 secretion of hDCs pulsed with polyomavirus-derived VLPs. The
hDCs were incubated with BKPyV-, JCPyV-, SV40-, MPyV- or HaPyV-derived
VLPs, “mock” VLPs and LPS. The supernatants of the hDCs were collected
after 48 h of incubation and stored frozen at −80 °C until analysis by IL-12
ELISA. Shown are the mean values and standard deviations of three
independent experiments.(untreated and “mock VLPs”-treated hDCs), a very low
frequency of CD8-positive, IFN-gamma secreting cells was
detected. The strongest increase of the frequency of specific T
cells was observed for MPyV- and in particular for HaPyV-
derived VLPs.
Chimeric HaPyV-VP1-derived VLPs harboring an enhanced
green fluorescent protein enabled the detection of the uptake
of VLPs by human dendritic cells
To study the uptake of HaPyV-derived VLPs, a HaPyV-VP1
derivative was generated harboring the enhanced green
fluorescent protein (eGFP) sequence at insertion site #4
(between amino acid residues 288 and 295) of HaPyV-VP1.
The intrinsic fluorescence of the eGFP in the yeast-expressedFig. 3. Frequency of VLP-reactive CD8-positive T cells. T cells were stimulated
twice with pulsed hDCs as described in Materials and methods and restimulated
with VP1-VLPs 16 h before the assay. The percentage of IFN-gamma secreting
cells was detected by PE-labeled IFN-specific detection antibody in a capture
assay. The T cells were marked with a CD8-FITC-conjugated antibody. A
representative of three independent experiments is shown. In the upper right
quadrant, the mean T-cell frequencies of three experiments with standard
deviation are indicated.
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band in the cesium chloride (CsCl) gradient after ultracentri-
fugation (data not shown). The migratory behavior of VP1/
eGFP in the gradient was found to be slightly different from that
of the unmodified VP1. This is reflected in the fact that the main
portion of VP1/eGFP was recovered in fractions corresponding
to densities of 1.27 to 1.29 g/cm3, whereas VP1 VLPs were
found in fractions with densities of 1.30 to 1.31 g/cm3 (data not
shown). A protein band of the expected molecular weight from
corresponding fractions (about 66 kDa) reacted with a rabbit
serum raised against the entire HaPyV-VP1 (aa 1–384) and
rabbit anti-GFP serum (data not shown). The VP1/eGFP fusion
protein tended to aggregate in high salt buffers and in
concentrations higher than 2 mg/ml. The formation of VLPs
was confirmed by negative staining electron microscopy. The
electron microscopic images of VP1/eGFP VLPs (Fig. 4A) were
found to be similar to those of VLPs generated by unmodified
VP1 (Fig. 4B).
Purified VP1/eGFP VLPs were used to analyze the VLP
uptake by monocyte-derived hDCs. Whereas after 12 and 16 h
of incubation, only traces of eGFP fluorescence were observedFig. 4. Detection of VLP formation by negative staining electron microscopy for
HaPyV-VP1/eGFP (A) and HaPyV-VP1 used for comparison (B).inside or in association with human DCs, incubation for 24 h
resulted in the internalization of the majority of VP1/eGFP
VLPs, as determined by fluorescence microscopy. In contrast,
in untreated cells (negative control), no green fluorescence
was observed by fluorescence microscopy (data not shown).
VLPs originating from VP1 of different polyomaviruses vary in
the efficiency of their uptake by human dendritic cells
Toexcludeapossible influenceofeGFPinsertionontheuptake
of polyomavirus-derivedVLPs, the different polyomavirusVP1-
derived VLPs were labeled with CFDA before incubating with
hDCs.First, a timecourse of theuptakeofCFDA-labeledHaPyV-
VLPsbyhDCswasestablishedby twoalternativeapproaches, i.e.
fluorescence microscopy (Fig. 5A) and FACS analysis of hDCs
(Fig. 5B). As documented by fluorescence microscopy, the
incubation of hDCs with CFDA-labeled HaPyV-VP1 VLPs
resulted in an increasing number of fluorescent cells, with the
majority of cells (>80%) being fluorescent after 60 min of
incubation (Fig. 5A). FACS analysis of hDCs incubated with
CFDA-labeled HaPyV-derived VLPs confirmed that after an
incubationperiodof120min92%of thecellshad takenupCFDA-
labeled VLPs (Fig. 5B), which did not increase after further
incubation. Based on this protocol established for HaPyV-VP1
VLPs, the uptake of CFDA-labeled VLPs of the other poly-
omaviruseswasmeasured (Fig. 5C).Theobserved level ofuptake
for HaPyV-derived VLPs at the 2 h endpoint was higher than that
for VLPs originating from MPyV and from the primate
polyomaviruses (BKPyV, JCPyVand SV40).
As a first approach to study receptor association, the VP1
VLPs of the different polyomaviruses (HaPyV, MPyV, SV40,
JCPyV and BKPyV) were tested for their hemagglutination
activity with guinea pig erythrocytes. The JCPyV-, BKPyV- and
MPyV-derived VLPs all demonstrated a strong hemagglutina-
tion activity down to a concentration of 2 pg/μl. In contrast,
HaPyV-derived VLPs were found to have no activity in the
hemagglutination assay. As already known for SV40, the SV40-
derived VLPs were also negative in this test (data not shown).
Discussion
Pulsing of hDCs with VP1-derived VLPs of rodent
polyomaviruses, i.e. HaPyV and MPyV, was found to induce
hDC maturation as shown by upregulation of CD80, CD83,
CD86, MHC-I and MHC-II. In addition to the upregulation of
maturation markers, in our approach, the VLP-induced matura-
tion of hDCs was confirmed functionally by the reduced uptake
of FITC–dextran and Lucifer Yellow. Moreover, VLP-pulsed
hDCs were found to secrete IL-12 and induce a VP1-reactive
CTL response in vitro as demonstrated by IFN-gamma
secretion. In contrast, VP1-derived VLPs originating from
SV40 or human polyomaviruses (JCPyV, BKPyV) demon-
strated only very weak or no maturation of hDCs and
correspondingly weak T-cell responses.
Potential reasons for the observed differences between
rodent and primate polyomavirus-derived VLPs in the induced
level of hDC maturation might be (i) intrinsic to the VLP
Fig. 5. Uptake of polyomavirus-derived VLPs by hDCs: time course of uptake of CFDA-labeled HaPyV-VP1 VLPs by hDCs determined by fluorescence microscopy
(A; lower row; for control, the corresponding representative areas of phase contrast images are given in the upper row) and FACS analysis (B; one representative of
three experiments) and comparison of the fluorescence intensity of hDCs after 2 h of incubation with CFDA-labeled VLPs of various polyomaviruses (C; the average
with standard deviation of three independent experiments is given).
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receptor association and uptake.
Recently, pentamers of carboxy-terminally truncated VP1 of
MPyV were found to be unable to induce host-specific
cytokines whereas on the contrary infectious virus and
corresponding VP1-derived VLPs were capable to elicit a
host-specific cytokine response in mice (Velupillai et al., 2006).
As reported by us earlier and confirmed by a large number of
independent expression and purification studies (Sasnauskas et
al., 2002), VP1 proteins of mammalian polyomaviruses
efficiently form VLPs. We have never seen pentamers or sub-
capsid assemblies in our electron microscopic images of
purified polyomavirus VLPs. If assuming that there will be a
low level of non-VLP structures in our preparations (pentamers
or sub-capsid assemblies) that is not detectable by electron
microscopy, as we have never seen differences in the assembly
capacity of these VP1 proteins, we would not expect differences
in the level of these contaminations between the VLPs of the
different mammalian polyomaviruses used in this study.
Therefore, it seems to be very unlikely that pentamers or sub-capsid assemblies in some VLP preparations inhibit the
response in our hDC studies. In contrast, the assembly capacity
of VP1 of avian polyomaviruses, at least in our yeast system,
was found to be less efficient (Sasnauskas et al., 2002; Zielonka
et al., 2006).
To study entry pathways and uptake levels of papilloma-
virus-derived VLPs, VLPs were labeled with CFDA (Fausch et
al., 2003) or by generating an eGFP-VLP fusion (Peng et al.,
1999). As site #4 in HaPyV-VP1 has been found, in line with the
corresponding site in MPyV-VP1 (Gleiter et al., 1999), to
tolerate large foreign insertions, we generated a HaPyV-VP1
derivative harboring the eGFP insert at this position. The
behavior of VP1/eGFP in the CsCl gradient and of the
assembled VLPs in the negative stain electron microscopy
confirmed the formation of VLPs, but slightly deviated from the
properties of authentic VP1 VLPs. Nevertheless, these chimeric
VLPs were able to demonstrate the uptake of HaPyV-derived
VLPs by hDCs (this paper) and murine DCs (Zvirbliene et al.,
2006) and might represent a useful tool for entry studies on
HaPyV which were hampered by the lack of an efficient cell
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influence of structural peculiarities due to the large eGFP insert
on the entry kinetics of HaPyV-derived VLPs, the comparative
study on the uptake level of different polyomavirus VP1-
derived VLPs was performed using CFDA-labeled VLPs.
Based on CFDA-labeled HaPyV-derived VLPs, a routine
protocol to study VLP uptake was established. This study
revealed that the level of uptake corresponds to the induced
maturation and functional activity of hDCs; the highest level of
uptake was observed for VLPs originating from HaPyV,
followed by MPyV, and the primate polyomaviruses.
The various uptake levels of the VLPs by hDCs might be the
consequence of individual receptor association differences.
Indeed, the tested VLPs differed in their ability to hemagglu-
tinate guinea pig erythrocytes. In line with previous data for the
corresponding infectious viruses (Bolen and Consigli, 1979;
Knowles et al., 2003), JCPyV-, BKPyV- and MPyV-derived
VLPs were found to agglutinate, whereas HaPyV- and SV40-
derived VLPs did not. In contrast, mouse pneumotropic virus-
derived VLPs were recently found to fail to hemagglutinate
erythrocytes (Tegerstedt et al., 2003). Although initial data of
competitive entry inhibitor studies suggest similar entry path-
ways for HaPyV-, SV40- and MPyV-derived VLPs, the varying
levels of inhibition observed might indicate a certain degree of
diversity (our unpublished data). These differences might be
caused by unique receptors used for SV40 and MPyV entry
(Basak et al., 1992; Breau et al., 1992; Stehle et al., 1994; Tsai et
al., 2003). These variations among VP1-derived VLPs
originating from different polyomaviruses in hemagglutination
activity as well as entry inhibition experiments might reflect the
diversity in receptor recognition among polyomaviruses.
In our study, the maturation potential of HaPyV-derived
VLPs was found to be slightly stronger than that of MPyV-
derived VLPs. Recently, it was described that authentic VP1
and VP1/VP3-eGFP MPyV-derived VLPs failed to induce an
upregulation of hDC maturation markers but readily triggered
an IL-12 secretion (Boura et al., 2005). This discrepancy to our
data might be explained by the different expression systems
used as well as experimental details.
The strong potential of HaPyV-derived VLPs is in line with
earlier data on the strong immunogenicity of these VLPs in
mice. As also observed for papillomavirus-derived VLPs, yeast-
expressed chimeric HaPyV-VP1 VLPs are able to induce strong
insert-specific immune responses without additional adjuvants
(Gedvilaite et al., 2004). Moreover, chimeric HaPyV-VP1-
derived VLPs were demonstrated to represent a useful tool for
generating monoclonal antibodies with desired specificity
(Zvirbliene et al., 2006). In addition, the yeast-expressed
HaPyV-VP1 was found to tolerate medium-sized foreign
insertions (120 aa in length) at certain insertion sites (Gedvilaite
et al., 2000, 2004). This high insertion capacity of HaPyV-VP1
is here confirmed by the formation of chimeric VLPs harboring
an eGFP at site #4 of HaPyV-VP1.
The observed differences between VLPs originating from
rodent and primate polyomaviruses might reflect the coevolu-
tion of these viruses and their natural hosts. Another explanation
for the different levels of maturation induced by VLPs fromrodent polyomaviruses (HaPyV and MPyV) and from primate
polyomaviruses (SV40, JCPyV, BKPyV) might be that rodent
polyomavirus-derived VLPs more extensively trigger pattern
recognition receptors inducing hDC maturation than primate
polyomavirus-derived VLPs. As a consequence, the antiviral T-
cell response can be more efficient. In line with this assumption,
the frequency of JCPyV-VP1-specific CTLs directed to two
HLA-A*0201-restricted epitopes was found to be low com-
pared to CTL frequencies observed for other DNA viruses like
herpesviruses EBV, CMV and HSV (Du Pasquier et al., 2003).
In addition, in a previous study, baculovirus-expressed human
polyomavirus JCPyV- and BKPyV-derived VP1 VLPs failed to
induce maturation of murine DCs, even at a concentration 100
times higher than that sufficient for phenotypic maturation by
papillomavirus-derived VLPs (Lenz et al., 2001). Similarly,
MPyV was found to infect myeloid- and lymphoid-related
murine DCs resulting in an efficient induction of polyomavirus-
specific CD8-positive T cells (Drake et al., 2000, 2001). To
allow a comparison of the maturation potential of VLPs of
rodent and primate polyomaviruses in hDCs and murine DCs,
future studies should explore these VLPs expressed in the same
heterologous system.
In conclusion, monocyte-derived hDCs internalized the
tested VP1-derived VLPs with different efficiencies. Exposure
to VLPs originating from HaPyV and MPyV thereby induced
maturation of hDCs resulting in activation of CD8-positive T-
cells. In contrast, VLPs derived from human polyomaviruses
(BK and JC) as well as SV40 were less potent. These data
offer important implications for development of polyomavirus
VLP-derived vaccines and gene transfer carriers and confirmed
the value of the HaPyV-based VLP system for these
applications.
Materials and methods
Antibodies
For the phenotypic flow cytometry analysis of hDC surface
markers, the following antibodies were used: anti-CD3 (clone
OKT3), anti-CD8 (clone HIT8a), anti-CD14 (clone M5E2),
anti-CD80 (clone MAB104), anti-CD83 (clone HB15e), anti-
CD86 (clone IT2.2), anti-HLA ABC (clone WG/32) and anti-
HLA DR DQ (clone Tü39). All antibodies were obtained from
BD Pharmingen (Heidelberg, Germany). The secondary anti-
bodies, PE-labeled goat-anti-mouse-IgG and FITC-labeled anti-
mouse-IgG, were purchased from Biozol Diagnostica (Eching,
Germany) and BD Pharmingen, respectively.
Generation of a HaPyV-VP1/eGFP fusion construct
All DNA manipulations were performed according to
standard procedures. Recombinants were screened in E. coli
K12 DH5α cells. The coding sequence for eGFP was
introduced in frame into position #4 (corresponding to aa
288–295) of the HaPyV-VP1-encoding sequence. For expre-
ssion in yeast, the VP1/eGFP fusion gene was cloned into the
pFX7 plasmid (Sasnauskas et al., 1999).
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VLPs consisting of the major capsid protein VP1 of HaPyV,
MPyV, SV40 or human polyomaviruses JCPyV and BKPyV as
well as chimeric VP1/eGFP VLPs were generated in yeast S.
cerevisiae and purified by CsCl gradient centrifugation as
described previously (Sasnauskas et al., 1999, 2002).As a control
(“mockVLPs”), a lysate of pFX7-transformed and induced yeast
cells was treated in the same way. A fraction of the CsCl gradient
corresponding to the fraction where usually VP1-VLPs can be
recoveredwas collected.VLP-containingCsCl gradient fractions
were collected and dialyzed against PBS. Subsequently, the
dialyzed samples were either mixed with glycerol (50%) or
lyophilized and stored at −20 °C until further use.
SDS polyacrylamide gel electrophoresis and Western blot
analysis
After VLP purification by CsCl gradient ultracentrifugation
and dialysis against PBS, aliquots of protein were boiled and
separated by 12% SDS polyacrylamide gels. Subsequently, gels
were stained by Coomassie blue or transferred onto PVDF type
Immobilon-P transfer membrane (Millipore Corporation, Bed-
ford, MA, USA) by semidry blotting. After transfer, the
membranes were blocked for 1 h with TBS (0.1 M Tris,
0.3 M NaCl, pH 7.4) with 5% dry milk/0.1% Tween 20.
Thereafter, the membranes were incubated for 2 h in rabbit sera
raised against E.-coli-expressed, entire HaPyV-VP1 (Voronkova
et al., 2002) or GFP (Invitrogen, Groningen, The Netherlands)
diluted 1:1000 and 1:5000, respectively, in TBS/0.1% Tween
20. As secondary antibody, the horse radish peroxidase (HRP)-
labeled anti-rabbit IgG conjugate (Amersham Life Science,
Hercules, CA, USA) was applied for 2 h. The HRP-mediated
staining was performed by adding 4-chloro-1-naphtol and H2O2
(Fluka, Buchs, Switzerland).
Electron microscopy
To confirm the formation of VLPs consisting of unmodified
VP1 from the different polyomaviruses and of HaPyV-VP1/
eGFP, CsCl gradient fractions were placed on 400-mesh carbon
coated palladium grids. Samples were stained with 2% aqueous
uranyl acetate solution and examined with a JEM-100S electron
microscope.
Generation of human monocyte-derived DCs
Isolation and cultivation of monocyte-derived hDCs were
performed as previously described (Pecher et al., 2002). Briefly,
heparinized (100 U/ml heparin, Liquemin; Hoffmann-La
Roche, Grenzach-Wyhlen, Germany) blood was drawn from
healthy donors and diluted with 1 volume RPMI-1640 medium
(Gibco). Peripheral blood mononuclear cells (PBMC) were
isolated over a Lymphoprep-Plaque (1.077 g/ml; Nycomed).
The PBMC were resuspended in RPMI-1640 and thrombocytes
were removed by washing four times by centrifugation
(1000 rpm, 10 min, 4 °C). Then, PBMC were pelleted,resuspended in X-vivo 15 (BioWhittaker; Walkersville, Mary-
land) and seeded at a concentration of 107 PBMC in 3 ml of
medium per well into 6-well plates (Falcon) to separate
monocytes by adhesion to plastic. After incubating for 2 h at
37 °C, monocytes were obtained by gently washing away the
contaminating non-adherent cells with pre-warmed RPMI-
1640. Immature hDCs were generated from adhesion-purified
monocytes by cultivating cells for 6 days in X-vivo 15
supplemented with 500 U/ml human recombinant IL-4 (AL-
ImmunoTools, Friesoythe, Germany) and 1000 U/ml recombi-
nant human granulocyte-macrophage colony-stimulating factor
(hGM-CSF). Half of the medium was changed every 2 days,
and cytokines added in the concentrations described above.
DC stimulation and pulsing
Immature hDCs were incubated with 10 μg/ml VLPs or
controls for 48 h at a concentration of 106 cells/ml of medium
containing 1000 U/ml hGM-CSF. As positive control, mature
hDCs were generated by incubation with 1 μg/ml of LPS
(Sigma, Deisenhofen, Germany). In addition to untreated cells,
a parallel preparation from pFX7-transformed and induced
yeast cells was used as a negative control (“mock VLPs”). Cells
were harvested, washed with PBS and subsequently stained for
FACS analysis or used for T-cell stimulation. Supernatants were
collected for IL-12 ELISA.
Flow cytometry of human DCs
After pulsing of hDCs, cells were harvested, washed with
PBS and subsequently stained for FACS analysis. To this end,
hDCs (1×105) were resuspended in FACS buffer (PBS
containing 2% FCS) and incubated with specific antibodies
against the following markers: CD83, CD80, CD86, HLA ABC
and HLA DR DQ. After 1 h of incubation, cells were washed
and stained with a PE-labeled secondary antibody for 1 h on ice.
Cells were analyzed using a FACSCalibur (Becton Dickinson,
Heidelberg) with CellQuest software (BD Pharmingen).
Determination of phagocytotic capacity
Pulsed hDCs were incubated with FITC–dextran (10 μg/ml)
or Lucifer Yellow (4%) for 1 h at 37 °C and 4 °C. The cells were
then washed three times with PBS and analyzed by flow
cytometry. The receptor-mediated uptake of FITC–dextran or
macropinocytosis of Lucifer Yellow was determined by
calculating the difference of the mean fluorescent intensities
at 37 °C and 4 °C. FITC–dextran was purchased from SIGMA
(Deisenhofen, Germany) and Lucifer Yellow from Molecular
Probes (Leiden, The Netherlands).
IL-12 assay
For the IL-12 ELISA, the supernatant of 106 hDCs stimulated
with 10 μg/ml VLPs for 48 h was collected. As negative control,
“mock VLPs”-treated cells were used. As positive control, hDCs
were treated with 1 μg/ml of LPS. Supernatants were collected
259A. Gedvilaite et al. / Virology 354 (2006) 252–260after spinning cells at 1000 rpm for 10 min. Subsequently, the
amount of IL-12 was determined with a commercially available
total IL-12 (p70 and p40) assay (Pierce Endogene, Cambridge,
MA) according to the protocol of the manufacturer.
T-cell stimulation assays
The specific stimulation of CD8-positive T cells with VLPs
was determined evaluating 5×105 autologous T cells and using
a commercially available IFN-gamma secretion assay following
the manufacturers' protocol (Miltenyi Biotec). T cells were
placed into 24-well plates (NUNC) at 1×106 cells/ml and were
stimulated with pulsed hDCs at a T cell/hDC ratio of 20:1 and
100 U/ml human recombinant interleukin-2 (IL-2; PeproTech,
London, UK). The hDC pulsing was performed as described for
the maturation analysis. As negative control, “mock VLPs”- and
untreated hDCs or LPS-maturated hDCs were included. After 5
days in co-culture, T cells were supplemented with 100 U/ml
IL-2 and restimulated with hDCs as before. Four days after the
second stimulation, T cells were prepared for T-cell stimulation
assays. The T cells were restimulated for 16 h with VLPs
(10 μg/ml) at 37 °C. To prepare for staining, cells were washed
twice with buffer (PBS with 1% FCS). The stimulated T cells
were then incubated with the IFN-gamma catch reagent for 5
min followed by a 45 min secretion phase at 37 °C. After the
secretion period, the cells were washed and incubated on ice
with the PE-labeled IFN-gamma detection antibody and CD8-
FITC mAb for 35 min. The number of IFN-gamma secreting
CD8-positive T cells was calculated as a percentage of IFN-
gamma and CD8-positive cells minus the number of IFN-
gamma- and CD8-positive cells in the negative control to the
total number of CD8-positive T cells.
Uptake of VLPs by human DCs
VLPs were labeled with 5-(and 6-) carboxyfluorescein
diacetate succinimidyl ester (CFDA; SIGMA-Aldrich, Munich,
Germany) according to a recently described protocol for
papillomavirus-derived VLPs (Fausch et al., 2003). Briefly,
VLPs were incubated with CFDA at room temperature. After 4 h
of incubation, VLPs were diluted 1:15 with PBS and ultracen-
trifuged at 36,000 rpm at 4 °C for 1 h. The pellet was resuspended
in0.5mlPBSandaddedto thehDCsataconcentrationof10μg/ml
VLP-CFDA for 12 h at 37 °C. The fluorescence intensity of the
hDCs was measured by flow cytometry.
Hemagglutination (HA) assays
VLPs were tested for their ability to hemagglutinate guinea
pig erythrocytes by incubating 0.1 ml of serially diluted VLPs
(50 ng/μl–0.025 pg/μl) with 0.1 ml of a 0.4% guinea pig
erythrocyte suspension at 4 °C for 4 h.
Acknowledgments
The authors would like to kindly acknowledge the support of
Drs. Detlev H. Krüger, Muhsin Özel and Siegfried Scherneck.We are very grateful to Gudrun Holland for excellent technical
assistance, Ulf Harnack for his excellent scientific advice and R.
Slibinskas for providing purified measles virus nucleoprotein.
The work was supported by the Internationales Büro der DLR/
BMBF (grant LTU 02/001), Lithuanian State Science and
Studies Foundation (grants no. 273 and V-11), Swedish Medical
Research Council, Stockholm Cancer Society, Swedish Cancer
Foundation, Gustav Vth Jubileum Society and Charité School
of Medicine. D.C.D. kindly acknowledges a medical research
fellowship award of the Charité School of Medicine. T.R. was
supported by EC grant LSHB-CT-2004-005246.References
Banchereau, J., Steinman, R.M., 1998. Dendritic cells and the control of
immunity. Nature 392, 245–252.
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J.,
Pulendran, B., Palucka, K., 2000. Immunobiology of dendritic cells. Annu.
Rev. Immunol. 18, 767–811.
Basak, S., Turner, H., Compans, R.W., 1992. Expression of SV40 receptors on
apical surfaces of polarized epithelial cells. Virology 190, 393–402.
Bolen, J.B., Consigli, R.A., 1979. Differential adsorption of polyoma virions
and capsids to mouse kidney cells and guinea pig erythrocytes. J. Virol. 32,
679–683.
Boura, E., Liebl, D., Spisek, R., Fric, J., Marek, M., Stokrova, J., Holan, V.,
Forstova, J., 2005. Polyomavirus EGFP-pseudocapsids: analysis of model
particles for introduction of proteins and peptides into mammalian cells.
FEBS Lett. 579, 6549–6558.
Breau, W.C., Atwood, W.J., Norkin, L.C., 1992. Class I major histocompa-
tibility proteins are an essential component of the simian virus 40 receptor.
J. Virol. 66, 2037–2045.
Chang, D., Fung, C.Y., Ou, W.C., Chao, P.C., Li, S.Y., Wang, M., Huang, Y.L.,
Tzeng, T.Y., Tsai, R.T., 1997. Self-assembly of the JC virus major capsid
protein, VP1, expressed in insect cells. J. Gen. Virol. 78, 1435–1439.
Drake III, D.R., Moser, J.M., Hadley, A., Altman, J.D., Maliszewski, C., Butz,
E., Lukacher, A.E., 2000. Polyomavirus-infected dendritic cells induce
antiviral CD8(+) T lymphocytes. J. Virol. 74, 4093–4101.
Drake III, D.R., Shawver, M.L., Hadley, A., Butz, E., Maliszewski, C.,
Lukacher, A.E., 2001. Induction of polyomavirus-specific CD8(+) T
lymphocytes by distinct dendritic cell subpopulations. J. Virol. 75, 544–547.
Du Pasquier, R.A., Kuroda, M.J., Schmitz, J.E., Zheng, Y., Martin, K., Peyerl,
F.W., Lifton, M., Gorgone, D., Autissier, P., Letvin, N.L., Koralnik, I.J.,
2003. Low frequency of cytotoxic T lymphocytes against the novel HLA-
A*0201-restricted JC virus epitope VP1(p36) in patients with proven or
possible progressive multifocal leukoencephalopathy. J. Virol. 77,
11918–11926.
Fausch, S.C., Da Silva, D.M., Kast, W.M., 2003. Differential uptake and cross-
presentation of human papillomavirus virus-like particles by dendritic cells
and Langerhans cells. Cancer Res. 63, 3478–3482.
Forstova, J., Krauzewicz, N., Wallace, S., Street, A.J., Dilworth, S.M., Beard, S.,
Griffin, B.E., 1993. Cooperation of structural proteins during late events in
the life cycle of polyomavirus. J. Virol. 67, 1405–1413.
Franzen, A.V., Tegerstedt, K., Hollanderova, D., Forstova, J., Ramqvist, T.,
Dalianis, T., 2005. Murine polyomavirus-VP1 virus-like particles immunize
against some polyomavirus-induced tumours. In Vivo 19, 323–326.
Gedvilaite, A., Frömmel, C., Sasnauskas, K., Micheel, B., Özel, M., Behrsing,
O., Staniulis, J., Jandrig, B., Scherneck, S., Ulrich, R., 2000. Formation of
immunogenic virus-like particles by inserting epitopes into surface-exposed
regions of hamster polyomavirus major capsid protein. Virology 273, 21–35.
Gedvilaite, A., Zvirbliene, A., Staniulis, J., Sasnauskas, K., Krüger, D.H.,
Ulrich, R., 2004. Segments of Puumala hantavirus nucleocapsid protein
inserted into chimeric polyomavirus-derived virus-like particles induce a
strong immune response in mice. Viral Immunol. 17, 51–68.
Gleiter, S., Stubenrauch, K., Lilie, H., 1999. Changing the surface of a virus
shell fusion of an enzyme to polyoma VP1. Protein Sci. 8, 2562–2569.
260 A. Gedvilaite et al. / Virology 354 (2006) 252–260Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., Amigorena, S., 2002.
Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev.
Immunol. 20, 621–667.
Knowles, W.A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D.W.,
Miller, E., 2003. Population-based study of antibody to the human
polyomaviruses BKVand JCV and the simian polyomavirus SV40. J. Med.
Virol. 71, 115–123.
Kosukegawa, A., Arisaka, F., Takayama, M., Yajima, H., Kaidow, A., Handa,
H., 1996. Purification and characterization of virus-like particles and
pentamers produced by the expression of SV40 capsid proteins in insect
cells. Biochem. Biophys. Acta 1290, 37–45.
Lenz, P., Day, P.M., Pang, Y.Y., Frye, S.A., Jensen, P.N., Lowy, D.R., Schiller,
J.T., 2001. Papillomavirus-like particles induce acute activation of dendritic
cells. J. Immunol. 166, 5346–5355.
Montross, L., Watkins, S., Moreland, R.B., Mamon, H., Caspar, D.L.D., Garcea,
R.L., 1991. Nuclear assembly of polyoma capsids in insect cells expressing
the major capsid protein VP1. J. Virol. 65, 4991–4998.
Moser, J.M., Lukacher, A.E., 2001. Immunity to polyoma virus infection and
tumorigenesis. Viral Immunol. 14, 199–216.
Moser, J.M., Gibbs, J., Jensen, P.E., Lukacher, A.E., 2002. CD94-NKG2A
receptors regulate antiviral CD8(+) T cell responses. Nat. Immunol. 3,
189–195.
Noad, R., Roy, P., 2003. Virus-like particles as immunogens. Trends Microbiol.
11, 438–444.
Pawlita, M., Müller, M., Oppenlander, M., Zentgraf, H., Herrmann, M., 1996.
DNA encapsidation by viruslike particles assembled in insect cells from the
major capsid protein VP1 of B-lymphotropic papovavirus. J. Virol. 70,
7517–7526.
Pecher, G., Haring, A., Kaiser, L., Thiel, E., 2002. Mucin gene (MUC1)
transfected dendritic cells as vaccine: results of a phase I/II clinical trial.
Cancer Immunol. Immunother. 51, 669–673.
Peng, S., Zhou, J., Frazer, I.H., 1999. Construction and production of fluorescent
papillomavirus-like particles. J. Tongji Med. Univ. 19, 170–174.
Pumpens, P., Grens, E., 2002. Artificial genes for chimeric virus-like particles.
In: Khudyakov, Y.E., Fields, H.A. (Eds.), Artificial DNA. Methods and
Applications. CRC Press LLC, Boca Raton, pp. 249–327.
Salter, R.D., Dong, X., 2001. Regulation of antigen capture, MHC biosynthesis,
and degradation by dendritic cells. In: Lotze, T.M., Thomson, A.W. (Eds.),
Dendritic Cells. Academic Press, Inc., San Diego, CA, pp. 151–163.
Salunke, D.M., Caspar, D.L.D., Garcea, R.L., 1986. Self-assembly of purified
polyomavirus capsid protein VP1. Cell 46, 895–904.
Sasnauskas, K., Buzaite, O., Vogel, F., Jandrig, B., Razanskas, R., Staniulis, J.,
Scherneck, S., Krüger, D.H., Ulrich, R., 1999. Yeast cells allow high-level
expression and formation of polyomavirus-like particles. Biol. Chem. 380,
381–386.
Sasnauskas, K., Bulavaite, A., Hale, A., Jin, L., Knowles, W.A., Gedvilaite,
A., Dargeviciute, A., Bartkeviciute, D., Zvirbliene, A., Staniulis, J., Brown,
D.W., Ulrich, R., 2002. Generation of recombinant virus-like particles of
human and non-human polyomaviruses in yeast Saccharomyces cerevisiae.
Intervirology 45, 308–317.
Scherneck, S., Ulrich, R., Feunteun, J., 2001. The hamster polyomavirus—A
brief review of recent knowledge. Virus Genes 22, 93–101.
Schmidt, U., Kenklies, J., Rudolph, R., Böhm, G., 1999. Site-specific
fluorescence labelling of recombinant polyomavirus-like particles. Biol.
Chem. 380, 397–401.Stehle, T., Yan, Y., Benjamin, T.L., Harrison, S.C., 1994. Structure of murine
polyomavirus complexed with an oligosaccharide receptor fragment. Nature
369, 160–163.
Szomolanyi-Tsuda, E., Le, Q.P., Garcea, R.L., Welsh, R.M., 1998. T-cell-
independent immunoglobulin G responses in vivo are elicited by live-virus
infection but not by immunization with viral proteins or virus-like particles.
J. Virol. 72, 6665–6670.
Szomolanyi-Tsuda, E., Brien, J.D., Dorgan, J.E., Garcea, R.L., Woodland,
R.T., Welsh, R.M., 2001. Antiviral T-cell-independent type 2 antibody
responses induced in vivo in the absence of T and NK cells. Virology
280, 160–168.
Tegerstedt, K., Andreasson, K., Vlastos, A., Hedlund, K.O., Dalianis, T.,
Ramqvist, T., 2003. Murine pneumotropic virus VP1 virus-like particles
(VLPs) bind to several cell types independent of sialic acid residues and do
not serologically cross react with murine polyomavirus VP1 VLPs. J. Gen.
Virol. 84, 3443–3452.
Tegerstedt, K., Franzen, A.V., Andreasson, K., Joneberg, J., Heidari, S.,
Ramqvist, T., Dalianis, T., 2005. Murine polyomavirus virus-like particles
(VLPs) as vectors for gene and immune therapy and vaccines against viral
infections and cancer. Anticancer Res. 25, 2601–2608.
Tsai, B., Gilbert, J.M., Stehle, T., Lencer, W., Benjamin, T.L., Rapoport, T.A.,
2003. Gangliosides are receptors for murine polyoma virus and SV40.
EMBO J. 22, 4346–4355.
Ulrich, R., Nassal, M., Meisel, H., Krüger, D.H., 1998. Core particles of
hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50,
141–182.
Ulrich, R., Lomonossoff, G.P., Krüger, D.H. (Eds.), 2002. NewDevelopments in
Viral Vaccine Technologies. Thematic Issue. Intervirology, vol. 45, pp. 4–6.
Velupillai, P., Garcea, R.L., Benjamin, T.L., 2006. Polyoma virus-like particles
elicit polarized cytokine responses in APCs from tumor-susceptible and-
resistant mice. J .Immunol. 176, 1148–1153.
Vlastos, A., Andreasson, K., Tegerstedt, K., Hollanderova, D., Heidari, S.,
Forstova, J., Ramqvist, T., Dalianis, T., 2003. VP1 pseudocapsids, but not a
glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infec-
tion in a T-cell immune deficient experimental mouse model. J. Med. Virol.
70, 293–300.
Voronkova, T., Grosch, A., Kazaks, A., Ose, V., Skrastina, D., Sasnauskas, K.,
Jandrig, B., Arnold, W., Scherneck, S., Pumpens, P., Ulrich, R., 2002.
Chimeric bacteriophage fr virus-like particles harboring the immunodomi-
nant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-
specific antibody response in rabbits and mice. Viral Immunol. 15, 627–644.
Voronkova, T., Kazaks, A., Ose, V., Özel, M., Scherneck, S., Pumpens, P.,
Ulrich, R., in press. Hamster polyomavirus-derived virus-like particles are
able to transfer in vitro encapsidated plasmid DNA to mammalian cells.
Virus Genes.
Welsh, R.M., Stepp, S.E., Szomolanyi-Tsuda, E., Peacock, C.D., 2002. Tumor
viral escape from inhibited T cells. Nat. Immunol. 3, 112–114.
Zielonka, A., Gedvilaite, A., Ulrich, R., Lüschow, D., Sasnauskas, K., Müller,
H., Johne, R., 2006. Generation of virus-like particles consisting of the
major capsid protein VP1 of goose hemorrhagic polyomavirus and their
application in serological tests. Virus Res. 120, 128–137.
Zvirbliene, A., Samonskyte, L., Gedvilaite, A., Voronkova, T., Ulrich, R.,
Sasnauskas, K., 2006. Generation of monoclonal antibodies of desired spec-
ificity using chimeric polyomavirus-derived virus-like particles. J. Immunol.
Methods 311, 57–70.
